HighTide Therapeutics, a Rockville, MD-based biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, raised $107M in Series C/C+ funding.
The round was led by TCM Healthcare Fund, with participation from Yuexiu Fund and Yuthai Fund.
The company intends to use the funds to advance multiple global development programs, including mid- to late-stage clinical trials, and the commercialization and business development of its pipeline.
Led by CEO Liping Liu, HighTide Therapeutics is a clinical-stage biopharmaceutical company focusing on the discovery and development of novel multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. The company’s lead drug candidate, HTD1801, is a new molecular entity, currently in clinical development for the treatment of type 2 diabetes (T2DM), nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC). The U.S. Food and Drug Administration (FDA) granted Fast Track designation to HTD1801 for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program.
FinSMEs
05/01/2023